<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00593905</url>
  </required_header>
  <id_info>
    <org_study_id>RC-4590</org_study_id>
    <secondary_id>RC #4590</secondary_id>
    <nct_id>NCT00593905</nct_id>
  </id_info>
  <brief_title>Pharmacogenomics in Pulmonary Arterial Hypertension</brief_title>
  <official_title>Pharmacogenomics in Pulmonary Arterial Hypertension: A Multi-Center International Study to Determine Whether in PAH Patients Clinical Associations Exist Between the Efficacy and Toxicity of Endothelin Receptor Antagonists and Several Gene Polymorphisms in Several Key Disease-Specific and Therapy Specific Genes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West Penn Allegheny Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sir Mortimer B. Davis - Jewish General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chest Medical Associates</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lung Diagnostics, Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Latter Day Saints Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Louisiana State University Health Sciences Center in New Orleans</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southeastern Lung Care</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Suncoast Lung Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Colorado</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sentara Norfolk General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bay Area Chest Physicians</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>West Penn Allegheny Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our goal is to determine clinically in Pulmonary Arterial Hypertension patients if
      associations exist between the efficacy and toxicity of sitaxsentan, bosentan, and
      ambrisentan and several gene polymorphisms in several key disease-specific and therapy
      specific genes. Also characterized is the relationship between these polymorphisms and the
      severity of Pulmonary Arterial Hypertension using either baseline hemodynamic or clinical
      surrogates for disease severity.

      Hypothesis: Polymorphisms influence the efficacy and toxicity of specific Pulmonary Arterial
      Hypertension therapy as well as development/severity of PAH via their effect on PA
      remodeling, drug response, or metabolism.

      This study requires a one time 8.5 ml blood sample and clinical data to be obtained at
      initiation of therapy, 4 months after initiation of therapy and 12 months after initiation of
      therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will make use of a large population of well defined patients with Pulmonary
      Arterial Hypertension who were enrolled in Encysive Pharmaceutical's STRIDE clinical trials
      or who have received bosentan or ambrisentan for 4 months or longer. This international study
      constitutes the largest clinical study of this deadly disease and in such has great potential
      to alter the clinical practice by revealing novel gene-drug interactions. This study tests
      the hypothesis by executing the following aims:

      Aim 1: Determine in Pulmonary Arterial Hypertension (the relationship between known
      disease-specific polymorphisms (Serotonin transporter gene and PAI HindIII) and variants in
      BMPR2 and SMAD4 with several well-defined clinical efficacy endpoints of sitaxsentan,
      bosentan, and ambrisentan therapy.

      Aim 2: Determine in Pulmonary Arterial Hypertension the relationship between existing
      potentially &quot;therapy-specific&quot; polymorphisms in the ET-1, ETAR, ETBR, NPR-C, prostacyclin
      receptor and prostacyclin synthase with several well-defined clinical efficacy endpoints of
      sitaxsentan, bosentan, and ambrisentan therapy.

      Aim 3: Characterize the relationship between any treatment effect, these polymorphisms and
      PAH severity, using either clinical data or clinical surrogates for disease activity.

      ***This study was funded by the NIH from 2005 - 2009. In August 2009 a no-cost extension was
      granted and this study continued until the end of July 2010. Currently the study is still
      active and does still have several active sites participating; however, the study is funded
      by the internal institution and there is no contributing federal funding.***
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2005</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>6 Minute Walk Test</measure>
    <time_frame>12 months after initiation of drug therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemodynamics - Right Heart Catheterization</measure>
    <time_frame>12 months after intitation of drug therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Borg</measure>
    <time_frame>12 months after initiation of drug therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Class - FC</measure>
    <time_frame>12 months after intitation of drug therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities</measure>
    <time_frame>12 months after initiation of drug therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Clinical Worsening</measure>
    <time_frame>12 months after initiation of drug therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decline in WHO Functional Class</measure>
    <time_frame>12 months after initiation of drug therapy</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1300</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <condition>Pulmonary Hypertension</condition>
  <condition>PAH WHO Group I</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>GROUP 1
Patients have to be currently enrolled or previously enrolled in STRIDE FPH01, FPH01-XC FPH02, FPH02x, FPH03, FPH04 or FPH06.
WHO Group 1 Pulmonary arterial Hypertension: Idiopathic, Familial, Associated with (APAH) Collagen vascular disease, congenital systemic-to-pulmonary shunts, portal hypertension, Drugs and toxins (e.g., anorexigens, rapeseed oil, L-tryptophan, methamphetamine, and cocaine), other (thyroid disorders, glycogen storage disease, Gaucher disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders, splenectomy) Associated with significant venous or capillary involvement, Pulmonary veno-occlusive disease, Pulmonary-capillary hemangiomatosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Group 2
Patients currently receiving bosentan or ambrisentan OR who have previously received bosentan or ambrisentan for greater than 4 (four) months.
WHO Group 1 Pulmonary Arterial Hypertension: Idiopathic, Familial, Associated with (APAH), collagen vascular disease, congenital systemic-to-pulmonary shunts, portal hypertension, drugs and toxins (e.g., anorexigens, rapeseed oil, L-tryptophan, methamphetamine, and cocaine), other (thyroid disorders, glycogen storage disease, Gaucher disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders, or splenectomy), associated with significant venous or capillary involvement, pulmonary veno-occlusive disease, or pulmonary capillary hemangiomatosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitaxsentan</intervention_name>
    <description>Sitaxsentan sodium 100 mg tablet every morning</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Sitaxsentan-Thelin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosentan, Ambrisentan</intervention_name>
    <description>Bosentan 125 mg tablet twice daily Ambrisentan 5-10 mg tablet once daily</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Bosentan-Tracleer</other_name>
    <other_name>Ambrisentan-Letairis</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients must have been diagnosed with WHO Group 1 Pulmonary Arterial Hypertension:
        Idiopathic, Familial or Associated with (APAH) Collagen vascular disease, congenital
        systemic-to-pulmonary shunts, portal hypertension, Drugs and toxins , other (thyroid
        disorders, glycogen storage disease, Gaucher disease, hereditary hemorrhagic
        telangiectasia, hemoglobinopathies, myeloproliferative disorders, splenectomy) Associated
        with significant venous or capillary involvement, Pulmonary veno-occlusive disease,
        Pulmonary-capillary hemangiomatosis. Patients currently therapy must include sitaxsentan,
        bosentan, or ambrisentan OR patients must have previously been treated with sitaxsentan,
        bosentan or ambrisentan for 4 months or longer.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        GROUP 1

          -  Patients have to be currently enrolled or previously enrolled in STRIDE FPH01,
             FPH01-XC FPH02, FPH02x, FPH03, FPH04 or FPH06.

          -  WHO Group 1 Pulmonary Arterial Hypertension: Idiopathic, Familial, Associated with
             (APAH) Collagen vascular disease, congenital systemic-to-pulmonary shunts, portal
             hypertension, Drugs and toxins (e.g., anorexigens, rapeseed oil, L-tryptophan,
             methamphetamine, and cocaine), other (thyroid disorders, glycogen storage disease,
             Gaucher disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies,
             myeloproliferative disorders, splenectomy) Associated with significant venous or
             capillary involvement, Pulmonary veno-occlusive disease, Pulmonary-capillary
             hemangiomatosis.

        GROUP 2

          -  Patients currently receiving bosentan or ambrisentan OR who have previously received
             bosentan or ambrisentan for greater than 4 (four) months.

          -  WHO Group 1 Pulmonary Arterial Hypertension: Idiopathic, Familial, Associated with
             (APAH), collagen vascular disease, congenital systemic-to-pulmonary shunts, portal
             hypertension, drugs and toxins (e.g., anorexigens, rapeseed oil, L-tryptophan,
             methamphetamine, and cocaine), other (thyroid disorders, glycogen storage disease,
             Gaucher disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies,
             myeloproliferative disorders, or splenectomy), associated with significant venous or
             capillary involvement, pulmonary veno-occlusive disease, or pulmonary capillary
             hemangiomatosis.

        Exclusion Criteria:

        GROUP 1

          -  Not enrolled in the Encysive Pharmaceutical's STRIDE study(sitaxsentan).

          -  Known infectious disease (HIV, Hepatitis).

        GROUP 2

          -  Never enrolled in the STRIDE study for sitaxsentan patients.

          -  Not currently or previously on bosentan or ambrisentan.

          -  Patients who were previously on bosentan or ambrisentan must have been on bosentan or
             ambrisentan for greater than 4 months.

          -  Known infectious disease (HIV, Hepatitis).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond L Benza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allegheny General Hospital/Allegheny-Singer Research Institute of West Penn Allegheny Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea L Nowicki, BA</last_name>
    <phone>412.359.3653</phone>
    <email>phgenotype@wpahs.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raymond L Benza, MD</last_name>
    <phone>412.359.3584</phone>
    <email>rbenza@wpahs.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea L Nowicki, BA</last_name>
      <phone>412-359-3653</phone>
      <email>anowicki@wpahs.org</email>
    </contact>
    <contact_backup>
      <last_name>Raymond L Benza, MD</last_name>
      <phone>412.359.3584</phone>
      <email>rbenza@wpahs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Raymond L Benza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.phassociation.org</url>
    <description>Pulmonary Hypertension Association website</description>
  </link>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2008</study_first_submitted>
  <study_first_submitted_qc>January 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2008</study_first_posted>
  <last_update_submitted>January 20, 2012</last_update_submitted>
  <last_update_submitted_qc>January 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West Penn Allegheny Health System</investigator_affiliation>
    <investigator_full_name>Raymond Benza</investigator_full_name>
    <investigator_title>Professor of Medicine, Drexel University College of Medicine, James Magovern Chair for Cardiovascular Research Director and Section Head Advanced Heart Failure, Transplant, Mechanical Circulatory Support and Pulmonary Hypertension Programs</investigator_title>
  </responsible_party>
  <keyword>Pulmonary Arterial Hypertension</keyword>
  <keyword>Pulmonary Hypertension</keyword>
  <keyword>Pharmacogenomics</keyword>
  <keyword>DNA Testing</keyword>
  <keyword>sitaxsentan</keyword>
  <keyword>bosentan</keyword>
  <keyword>ambrisentan</keyword>
  <keyword>elevated pulmonary artery pressures</keyword>
  <keyword>Letairis</keyword>
  <keyword>Tracleer</keyword>
  <keyword>Thelin</keyword>
  <keyword>Primary Pulmonary Hypertension</keyword>
  <keyword>Pulmonary Artery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
    <mesh_term>Ambrisentan</mesh_term>
    <mesh_term>Sitaxsentan</mesh_term>
    <mesh_term>Endothelin Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

